Syndax Pharmaceuticals (SNDX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jul, 2026Opening remarks and agenda
Meeting commenced with introductions of board members, executive team, and auditors present for the session.
Agenda included formal business, voting on proposals, and a Q&A session for stockholders.
Board and executive committee updates
Board members and executive officers were introduced, including CEO, CFO, general counsel, and external auditors.
Shareholder proposals
Five proposals were presented: election of two class 1 directors, advisory approval of executive compensation, ratification of independent auditors, approval of the 2026 Equity Incentive Plan, and approval of the 2026 Employee Stock Purchase Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Syndax Pharmaceuticals
- Q2 2026 revenue surged 92% YoY, driven by Revuforj and Niktimvo growth and pipeline advances.SNDX
Q2 2026 - Expanding pipeline and late-stage programs drive growth and value across major indications.SNDXR&D Day 2026
- Rapid sales growth and pipeline expansion position for multi-billion dollar market leadership.SNDXH.C. Wainwright 27th Annual Global Investment Conference
- Two product launches target multi-billion dollar markets with robust early adoption and expansion plans.SNDXTD Cowen 45th Annual Healthcare Conference
- Rapid market penetration and robust pipeline position the business for significant growth.SNDXGoldman Sachs 47th Annual Global Healthcare Conference 2026
- FDA approved Revuforj for KMT2A+ acute leukemia, launching November 2024 with broad support.SNDXFDA Announcement
- FDA approval, $350M royalty deal, and strong cash reserves drive commercial readiness.SNDXQ3 2024
- FDA approves Niktimvo for refractory chronic GVHD, with U.S. launch expected by early Q1 2025.SNDXFDA Announcement
- Q1 2025 saw $33.6M in new product sales, $84.8M net loss, and $602.1M in cash reserves.SNDXQ1 2025